Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINC 3
NCT02180217Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of osilodrostat in Cushing's disease (CD), sponsored by Novartis. Started Oct 2014; status: completed.
02
Drugs
osilodrostat
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT02180217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02180217.